Simplifying Global Compliance
Amgen’s Next-Generation Heart Drug Enters Phase III with Positive Results
Washington Drug Letter
Amgen’s first long-term trial for its next-generation heart drug evolocumab has shown positive results, heating up the race to develop the emerging class of drugs known as PCSK9 inhibitors.
To View This Article:
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing